| 2019-09-12 07:26:53|
NTRA 07:26 09/12 09/12/19
Natera reiterated a Top Pick at Canaccord
Canaccord analyst Mark Massaro met with Natera management and came away confident in his view the shares remain an undervalued cancer company trading at the multiple of an NIPT company. The analyst said its near-term pipeline is loaded and the company is expected to announce oncology deals in the near future. Massaro reiterated his Buy rating and $38 price target on Natera shares.